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Free-radical scavenger edaravone inhibits both
formation and development of abdominal aortic
aneurysm in rats
Keisuke Morimoto, MD, Tomomi Hasegawa, MD, PhD, Akiko Tanaka, MD, Bao Wulan, MD,
Jie Yu, MD, Naoto Morimoto, MD, PhD, Yutaka Okita, MD, PhD, and Kenji Okada, MD, PhD, Kobe,
Japan
Objective:An ideal pharmaceutical treatment for abdominal aortic aneurysm (AAA) is to prevent aneurysm formation and
development (further dilatation of pre-existing aneurysm). Recent studies have reported that oxidative stress with
reactive oxygen species (ROS) is crucial in aneurysm formation. We hypothesized that edaravone, a free-radical scavenger,
would attenuate vascular oxidative stress and inhibit AAA formation and development.
Methods: An AAA model induced with intraluminal elastase and extraluminal calcium chloride was created in 42 rats.
Thirty-six rats were divided three groups: a low-dose (group LD; 1 mg/kg/d), high-dose (group HD; 5 mg/kg/d), and
control (group C, saline). Edaravone or saline was intraperitoneally injected twice daily, starting 30 minutes before
aneurysm preparation. The remaining six rats (group DA) received a delayed edaravone injection (5 mg/kg/d)
intraperitoneally, starting 7 days after aneurysm preparation to 28 days. AAA dilatation ratio was calculated. Pathologic
examination was performed. ROS expression was semi-quantified by dihydroethidium staining and the oxidative product
of DNA induced by ROS, 8-hydroxydeoxyguanosine (8-OHdG), by immunohistochemical staining.
Results: At day 7, ROS expression and 8-OHdG-positive cells in aneurysm walls were decreased by edaravone treatment
(ROS expression: 3.0  0.5 in group LD, 1.7  0.3 in group HD, and 4.8  0.7 in group C; 8-OHdG-positive cells:
106.2  7.8 cells in group LD, 64.5  7.7 cells in group HD, and 136.6  7.4 cells in group C; P < .0001), compared
with group C. Edaravone treatment significantly reduced messenger RNA expressions of cytokines and matrix metallo-
proteinases (MMPs) in aneurysm walls (MMP-2: 1.1 0.5 in group LD, 0.6 0.1 in group HD, and 2.3 0.4 in group
C; P < .001; MMP-9: 1.2  0.1 in group LD, 0.2  0.6 in group HD, and 2.4  0.2 in group C; P < .001). At day 28,
aortic walls in groups LD and HDwere less dilated, with increased wall thickness and elastin content than those in group
C (dilatation ratio: 204.7% 16.0% in group C, 156.5% 6.6% in group LD, 136.7% 2.0% in group HD; P< .0001).
Delayed edaravone administration significantly prevented further aneurysm dilatation, with increased elastin content
(155.2%  2.9% at day 7, 153.1%  11.6% at day 28; not significant).
Conclusions: Edaravone inhibition of ROS can prevent aneurysm formation and expansion in the rat AAA model.
Free-radical scavenger edaravone might be an effective pharmaceutical agent for AAA in clinical practice. ( J Vasc Surg
2012;55:1749-58.)
Clinical Relevance: Effective pharmaceutical treatment for abdominal aortic aneurysm (AAA) has not been yet estab-
lished. Many patients are followed up with sequential radiologic evaluation but with no options for medical treatment at
present. Edaravone is highly expected to be useful to prevent AAA formation and develop as an effective pharmaceutical agent.
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oAbdominal aortic aneurysm (AAA) represents a poten-
tially life-threatening condition characterized by transmu-
ral aortic wall degeneration, leading to dilatation, progres-
sive growth, and eventual rupture. In the clinical settings,
AAA typically has no signs or symptoms and can cause high
morbidity and death.1 There are currently no effective
approaches to prevent AAA, except invasive surgical or
endovascular therapies.
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doi:10.1016/j.jvs.2011.11.059AAA is a complex multifactorial disease with a still
nknown etiology. Histologically, the AAA is characterized
y mural inflammatory cell infiltration, destruction of elas-
in and collagen in the media and adventitia, and smooth
uscle cell loss, with thinning of the medial wall. Recent
tudies revealed that inflammation and oxidative stress are
ajor pathogenic mediators of AAA. Reactive oxygen spe-
ies (ROS) are abundantly produced by inflammatory cells.
xidative stress, generated by excessive ROS, is thought to
isturb the balance between destruction and regeneration
f the aortic wall by enhancing matrix proteolysis and
ugmenting subsequent inflammatory responses.2 ROS
evel and oxidative stress are greater in AAAs compared
ith nonaneurysmal aortic walls.3-6
Although pharmacologic treatment for AAA has not
een established clinically, experimental studies have dem-
nstrated that genetic and pharmacologic inhibition of
OS production can inhibit aneurysm formation.7 Edara-
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June 20121750 Morimoto et alvone (3-methyl-1-phenyl-2-pyrazoline-5-one) is a powerful
antioxidative free-radical scavenger that has been approved as
a therapeutic agent for acute cerebral infarction.8,9 Edara-
vone is a lipophilic agent with a low molecular weight
(174.20 kDa), so that it is readily accessible to tissue.10
Edaravone can eradicate toxic free radicals, including hy-
droxyl radicals. Experimental animal models have demon-
strated it has protective effects against oxidative stress in
many organs, including the aorta.11
A promising pharmacologic approach inhibits not only
AAA formation (newly created aneurysm) but also AAA
development (further dilatation of a pre-existing aneu-
rysm). In the present study, we hypothesized that the
free-radical scavenger edaravone could prevent aneurysm
formation and development.
METHODS
Rats. This study used 42 male Sprague-Dawley rats (8
weeks old, SLC Inc, Shizuoka, Japan). The handling of
laboratory animals and their use in experiments conformed
to the Guidelines for Animal Experiments at Kobe Univer-
sity Graduate School of Medicine (permission number:
P100608) and theGuide for the Care andUse of Laboratory
Animals (http://www.nap.edu/catalog/5140.html).
AAA preparation. An experimental AAA model was
created by means of simple application of intraluminal
elastase and extraluminal calcium chloride, according to
our recent report.12 Briefly, rats anesthetized with an intra-
peritoneal administration of pentobarbiturate (1 mg/kg)
were placed under an operating Leica M651 microscope
(Leica Microsystems, Heerburgg, Switzerland; original
magnification, 6 to 10). After a midline abdominal
incision and an abdominal aorta exposure, 30 units of
elastase (135 U/mg; Elastin Products, Owensville, Mo)
Fig 1. Edaravone or saline was intraperitoneally injected
Rats in the low-dose group (Group LD) received 1 mg
received 5 mg/kg/d edaravone, and control rats (Group
(Group DA) received 5 mg/kg/d edaravone starting at 7
chain reaction; ROS, reactive oxygen species.were applied to the 1-cm infrarenal aorta intraluminally and w.5 mmol/L of CaCl2 (Sigma-Aldrich, Tokyo, Japan) ex-
raluminally for 20 minutes. The abdominal incision was
losed in layers, and the rats were allowed to recover.
Edaravone administration. Edaravone was provided
y Mitsubishi, Tanabe Pharma Corporation (Tokyo, Ja-
an). Edaravone was dissolved in 1NNaOH and titrated to
H 7.0 with 1 N HCl. Two different doses (1 mg/kg/d
nd 5 mg/kg/d) were examined for AAA-preventable ef-
ects. The lower dose is usually used for clinical situations in
apan,13 and the higher dose is commonly used for animal
xperiments.14-17 Both doses were reported to be sufficient
or scavenging of hydroxyl radicals.
Thirty-six rats were randomly divided into one of three
roups (n  12 each): group LD received low-dose edara-
one (1 mg/kg/d), group HD received high-dose edara-
one (5 mg/kg/d), and group C received saline control
reatment. Edaravone or saline was intraperitoneally in-
ected twice daily, starting 30 minutes before aneurysm
reparation. Six rats received a delayed edaravone (group
A) injection (5 mg/kg/d) intraperitoneally, starting 7
ays after aneurysm preparation to 28 days (Fig 1).
Macroscopic assessments. Animals were anesthe-
ized, and the abdominal aorta was exposed. The aneurysm
iameter, defined as the maximal dimension, and the aortic
iameter at the infrarenal proximal neck site were measured
nder physiologic conditions with an optical micrometer
efore harvest. Dilation ratio (%) was calculated according
o the following formula: Dilation ratio (%)  (maximal
neurysm diameter/native aortic diameter)  100. The
arvested aortic aneurysm was divided into three portions.
he first portion was for a pathologic examination, the
econd portion for in situ imaging for superoxide, and the
hird portion for polymerase chain reaction (PCR) analysis.
Histology. Paraffin-embedded 5-m-thick sections
a day, starting 30minutes before aneurysm preparation.
d edaravone, rats in the high-dose group (Group HD)
eceived saline. Rats in the delayed administration group
after aneurysm preparation to 28 days. PCR, Polymerasetwice
/kg/
C) r
daysere stained by hematoxylin and eosin for general appear-
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Volume 55, Number 6 Morimoto et al 1751ance, elastica Van Gieson (EVG) for elastin, and terminal
deoxynucleotidyl transferase-mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) for apoptosis.
Images for the sections were captured with microscopicsys-
tem Biozero (BZ 8100, KEYENCE Co, Osaka, Japan) and
assessed by using software Dynamic cell count BZ-HIC
(KEYENCE).
The thickness of aortic wall was measured from the
average thickness between the luminal line of the aorta and
external elastic lamina at eight points of the cross-sectional
aortic wall in the EVG-stained sections. Areas of elastin in a
cross-sectional aortic wall were measured using software
Dynamic cell count BZ-HIC. Elastin content was calcu-
lated by dividing the elastin-positive area by cross-sectional
media area of the aortic wall, which was measured using the
EVG-stained sections to highlight internal elastic lamina
and external elastic lamina. Elastin content was expressed as
a percentage. Microscopic digital images of five random
fields on each section were scanned in a frame composed of
a 500-m  380-m rectangle, and the number of
TUNEL-positive cells in the aneurysm wall were counted
using software Dynamic cell count BZ-HIC.
Immunohistochemistry. Immunohistochemical stain-
ing was performed on paraffin-embedded sections with
monoclonal antibody specific for 8-hydroxydeoxyguanos-
ine (8-OHdG; Japan Institute for the Control of Aging,
Shizuoka, Japan) and for CD3 (Dako, Carpinteria, Calif).
Briefly, deparaffined sections were incubated overnight at
4°C with primary antibody against 8-OHdG (5.0g/mL).
After three washes, sections were incubated for 30 minutes
in secondary antibody antimouse immunoglobulin G
(K4001; Dako) at room temperature. Deparaffined sec-
tions also were incubated overnight at 4°C with primary
antibody against CD3 (0.3 g/mL). After three washes,
sections were incubated for 30 minutes in secondary anti-
body goat antirabbit immunoglobulin G (K4003; Dako) at
room temperature. Microscopic digital images of five ran-
dom fields on each section were scanned in a frame com-
posed of a 500-m  380-m rectangle, and the number
of 8-OHdG-positive cells and CD3-positive cells in aneu-
rysm wall were counted using software Dynamic cell count
BZ-HIC.
In situ imaging of superoxide. The harvested aortic
aneurysm was embedded in Tissue-Tek optimal cutting
temperature compound (Sakura Finetek, Zoeterwoude,
TheNetherlands), immediately frozen, and cut into 10-m
sections. Dihydroethidium (DHE; Invitrogen, Tokyo, Ja-
pan) was used to evaluate tissue superoxide levels in situ, as
previously described.18 The sections were incubated with
DHE in phosphate-buffered saline in a dark, humidified
chamber for 30 minutes at 37°C. DHE fluorescence was
detected through a 580-nm filter, and DHE fluorescence
images were scanned with Biozero in a frame composed of
a 500-m  380-m rectangle. DHE fluorescence of
arterial sections was quantified using software Dynamic cell
count BZ-HIC. The mean fluorescence was semi-quanti-
fied and expressed relative to values obtained for native rat. tQuantitative real-time PCR analysis. Total RNA
as isolated from the aneurysm samples using an RNeasy
brous tissue mini-kit (Qiagen, Valencia, Calif) according
o the manufacturer’s instructions. RNA was transcribed
nd amplified to complementary DNA (cDNA) using a
igh-capacity cDNA reverse-transcription real-time PCR
it (Applied Biosystems, Foster City, Calif). Quantitative
eal-time PCR analysis for mRNA of tumor necrosis factor
TNF)-, interleukin (IL)-1, and matrix metalloprotei-
ase (MMP)-2 and MMP-9 was performed using ABI
rism 7500 sequence detector system (Applied Biosys-
ems) with TaqMan universal PCR master mix and Taq-
an real-time PCR primers (Applied Biosystems). The
xpression level of each mRNA was divided by mRNA level
f the housekeeping gene glyceraldehyde-3-phosphate
ehydrogenase.
Delayed administration with edaravone. The group
A rats (n  6) were intraperitoneally injected with 5
g/kg/d edaravone starting at day 7. At 28 days after
neurysm preparation, rats were deeply anesthetized with
n intraperitoneal administration of pentobarbiturate (1
g/kg), and analysis was performed.
Statistical analysis. Continuous variables are ex-
ressed as mean standard deviation. Comparisons among
ultiple groups were performed using one-way analysis of
ariance (ANOVA), whereas comparisons between two
roups were made using the Student t test. All P values
ere two-sided and considered statistically significant at
.05. If the one-way ANOVA was significant, a post hoc
nalysis with the Games-Howell test was used to determine
he significance among the groups. Data were analyzed
ith SPSS 15 software (SPSS Inc, Chicago, Ill).
ESULTS
The surgical procedure in each group required approx-
mately 30 minutes to complete. No technical failures or
eaths occurred intraoperatively. All animals survived until
ach end point without complications.
Macroscopic assessments. Macroscopic findings at
ay 28 are shown in Fig 2. Aortic dilatation and dilatation
atio in the edaravone treatment groups (groups LD and
D) were significantly lower than in control rats (group
). The dilatation ratio in group HD was significantly
educed with edaravone compared with group LD (Table).
Microscopic assessments. Microscopic findings at
ay 28 are shown in Fig 3. The aortic wall thickness in the
daravone treatment groups exceeded that in group C
131.3  16.7 m in group LD, 141.8  16.6 m in
roup HD, and 115.4 11.1 m in group C; Fig 3,A and
). Elastin content in the aortic wall increased in the
daravone treatment groups significantly compared with
roup C (10.1%  0.7% in group LD, 12.4%  0.7% in
roup HD, and 7.8%  0.6% in group C; Fig 3, B and C).
here were dose-dependent increases between groups LD
nd HD in both aortic wall thickness and elastin content.
Effect of edaravone on ROS expression and
-OHdG inAAAwalls. To observe an ROS expression in
he aneurysm wall at day 7, DHE staining was performed.
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June 20121752 Morimoto et alROS expression in the aneurysm wall was significantly
suppressed in the edaravone treatment groups compared
with group C (3.0  0.5 in group LD, 1.7  0.3 in group
HD, and 4.8  0.7 in group C; Fig 4, A and B).
We next evaluated oxidative stress in the aneurysm wall
Fig 2. The panels show aneurysm formation of the abdominal
aorta at 28 days in each group. Control rats (Group C) received
saline administration; the low-dose rats (Group LD) received 1
mg/kg/d edaravone, and the high-dose rats (Group HD) received
5 mg/kg/d edaravone.
Table. Dilatation ratio for control and experimental
groups (%)a
Group Day 7 Day 28
Group C 155.2  2.9 204.7  16.0
Group LD 151.9  7.0 156.5  6.6b
Group HD 146.1  2.0 136.7  2.0b,c
Group C, Rats received saline administration as a control; Group LD, rats
received low-dose edaravone (1 mg/kg/d); Group HD, rats received high-
dose edaravone (5 mg/kg/d).
Statistical analysis was done using one-way analysis of variance with post hoc
Games-Howell test.
aDilation ratio (%) was calculated according to the following formula:
dilation ratio (%) (maximal aneurysm diameter/native aortic diameter)
100.
bP  .01 vs group C.
cP  .01 vs group LD at same day.by measuring 8-OHdG as a marker of oxidative DNA camage.19 The number of 8-OHdG-positive cells in aneu-
ysm walls was significantly decreased in the edaravone
reatment groups compared with group C (106.2  7.8
ells in groupLD, 64.5 7.7 cells in groupHD, and 136.6
.4 cells in group C; Fig 5, A and B). Significant dose-
ependent suppression was noted between groups LD and
D in ROS expression and 8-OHdG staining in the aneu-
ysm wall.
Effect of edaravone on cell apoptosis and inflamma-
ory cell infiltration. Cell apoptosis and inflammatory cell
nfiltration are strongly associated with oxidative stress. The
umber of TUNEL-positive cells in aneurysm walls was
ignificantly decreased in the edaravone treatment groups
ompared with group C (74.2  11.7 cells in group LD,
9.2  5.1 cells in group HD, and 180.7  11.1 cells in
roup C; Fig 6, A and B). Inflammatory cells, especially T
ymphocytes, were described to have interaction with apo-
tosis. The number of CD3-positive cells in aneurysm walls
as significantly decreased in the edaravone treatment
roups compared with group C (17.7  3.1 cells in group
D, 4.0  1.3 cells in group HD, and 78.5  9.9 cells in
roup C; Fig 7, A and B).
Effect of edaravone on TNF-, IL-1, MMP-2,
nd MMP-9 expression. Because aneurysmal degenera-
ion involves destructive remodeling of aortic wall connec-
ive tissues associated with chronic inflammation and exces-
ive local production of matrix-degrading proteinases, we
valuated mRNA expression of TNF-, IL-1, MMP-2,
nd MMP-9 in the aneurysm wall at day 7. mRNA expres-
ion of all of these was significantly inhibited in group HD
ompared with group C (Fig 8).
Effect of delayed administration with edaravone. For
linical application, an AAA must be regressed by pharma-
ologic treatment because the AAA always pre-exists when
t is found. Therefore, we assessed the effect of delayed
dministration with edaravone on further dilatation of pre-
xisting AAAs. At day 28, the dilatation ratio in group DA
as significantly lower than that in group C (153.1% 
1.6% in group DA and 204.7%  16.0% in group C).
oreover, the difference in the dilatation ratio between day
and day 28 in group DA was not statistically significant
155.2% 2.9% at day 7 vs 153.1% 11.6% at day 28; Fig
,A). Aortic wall thickness in group DA had a trend to be
hicker at day 28 than that in group C, although there
as no statistically significant difference in group DA
129.8 16.2 m) or in group C (115.4 11.1 m; Fig
, B). Significantly more elastin content was found in
roup DA (10.3  0.7%) than in group C (7.8%  0.6%;
ig 9, C).
ISCUSSION
The hypothesis in the present study is that AAAs de-
elop in the setting of oxidative stress generated by exces-
ive ROS, which is one of the possible contributors to
rterial wall degeneration. The notable finding of this study
s that the free-radical scavenger edaravone can decrease the
nflux of inflammatory cells that could account for de-
reased oxygen radical damage and cytokine and MMP
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Volume 55, Number 6 Morimoto et al 1753expression, totally, leading to prevention of AAA forma-
tion. Interestingly, delayed edaravone treatment also pre-
vented further dilatation of pre-existing AAAs.
Although ROS is important in the physiologic regula-
tion of vascular signal transductions, animal and human
studies have shown that aneurysmwalls have excessive ROS
expression (superoxide and hydrogen peroxide, hydroxyl
radical, and reactive nitrogen species).2-6,20-22 The exces-
sive ROS mediate activation of matrix-degrading proteins
Fig 3. Histologic findings of abdominal aortic aneurys
assessment of aortic wall thickness and (B) elastica van G
are at original magnification,40 (bar 300m), and th
m). C,Quantitative analysis of aortic wall thickness and
bars) for six rats per group. Statistical analysis was by on
*P  .05, **P  .01 vs group C, †P  0.01 vs the LD
administration as a control; Group LD, rats received lo
high-dose edaravone (5 mg/kg/d).and inflammatory responses, resulting in medial elastin reduction and aortic wall thinning and leading to aneurysm
ormation.23-27 In the present study, aneurysm formation
as also associated with increased ROS expression and
xidative DNA damage (8-OHdG-positive cells) in the
ortic wall. Apoptosis and T lymphocytes infiltration
ere suppressed in the aneurysm wall. mRNA expression
f TNF-, IL-1, MMP-2, and MMP-9 was overex-
ressed in the aneurysm walls, thus leading to the deduc-
ion that ROS was crucial in aneurysm formation in our
day 28 stained with (A) hematoxylin and eosin for the
for the assessment of elastin content. The upper panels
er panels are at original magnification,400 (bar 100
in content is shown as mean standard deviation (error
analysis of variance with post hoc Games-Howell test.
up. Native, Normal rats; Group C, rats received saline
se edaravone (1 mg/kg/d); Group HD, rats receivedm at
iesen
e low
elast
e-way
gro
w-doat AAA model.
received high-dose edaravone (5 mg/kg/d).
JOURNAL OF VASCULAR SURGERY
June 20121754 Morimoto et alFig 5. A, Immunostaining of 8-hydroxydeoxyguanosine (8-OHdG)-positive cells in aneurysm walls at day 7 are
shown (original magnification,400). B, The number of 8-OHdG–positive cells was counted in the high-power field.
All data are expressed as mean standard deviation (error bars) for six rats per group. Statistical analysis was done using
one-way analysis of variance with post hoc Games-Howell test. *P  .001 vs all other groups. Native, Normal rats;
Group C, rats received saline administration as a control; Group LD, rats received low-dose edaravone (1 mg/kg/d);Fig 4. Reactive oxygen species production in aneurysm walls at day 7. A, In situ detection of superoxide by
dihydroethidium stain is shown (upper panels, original magnification,40; lower panels, original magnification,400).
B, The mean fluorescence in high-power field was quantified and expressed as values for native rat; with all data are
expressed as mean  standard deviation (error bars) for six rats per group. Statistical analysis was done with one-way
analysis of variance with post hoc Games-Howell test. *P .01 vs all other groups.Native,Normal rats; Group C, rats
received saline administration as a control; Group LD, rats received low-dose edaravone (1 mg/kg/d); Group HD, ratsGroup HD, rats received high-dose edaravone (5 mg/kg/d).
I
p
i
e
p
s
oup H
JOURNAL OF VASCULAR SURGERY
Volume 55, Number 6 Morimoto et al 1755Aneurysm formation can be inhibited by antioxidative
effects, theoretically. Some antioxidant treatments, such as
apocynin7 and vitamin E,22 were recently reported to pre-
vent AAA formation. Edaravone is a widely used free-
radical scavenger in patients with acute cerebral infarc-
tion,28,29 and oral administration of edaravone also
Fig 6. A, Terminal deoxynucleotidyl transferase-media
assays in aneurysm walls at day 7 are shown (original ma
was counted in the high-power field. All data are expres
group. Statistical analysis was done with one-way analysi
group C, †P 0.01 vs group LD.Native,Normal rats; G
LD, rats received low-dose edaravone (1 mg/kg/d); Gr
Fig 7. A, Immunostaining of CD3-positive cells in aneu
B, The number of CD3-positive cells was counted in the
deviation (error bars) for six rats per group. Statistical anal
Games-Howell test. *P .001 vs all other groups.Nativ
a control;Group LD, rats received low-dose edaravone (1
mg/kg/d).inhibited production of free radicals in an in vivo study.30 tn cardiovascular fields, edaravone significantly reduces
ostoperative tissue damage in animal models of spinal cord
schemic injury.31,32 The present study demonstrated that
daravone has antioxidant properties that can act as a
owerful ROS scavenger in AAA formation. Edaravone
uppressed oxidative DNA damage, medial elastin reduc-
eoxyuridine triphosphate nick-end labeling (TUNEL)
ation, 400). B, The number of TUNEL-positive cells
mean  standard deviation (error bars) for six rats per
ariance with post hoc Games-Howell test. *P  .001 vs
C, rats received saline administration as a control; Group
D, rats received high-dose edaravone (5 mg/kg/d).
walls at day 7 are shown (original magnification,400).
-power field. All data are expressed as mean  standard
as done using one-way analysis of variance with post hoc
rmal rats; Group C, rats received saline administration as
kg/d);Group HD, rats received high-dose edaravone (5ted d
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June 20121756 Morimoto et alinal aorta. mRNA expressions of IL-1, TNF-, MMP-2,
and MMP-9 in the aortic wall were effectively decreased
through ROS elimination by edaravone treatment. Previ-
ous studies have shown that MMP-2 and MMP-9 are
required for AAA formation33,34 and that ROS induce
apoptosis of vascular smooth muscle cells.26,27 These find-
ings strongly suggest that edaravone ameliorates oxidative
aortic wall degeneration, resulting in prevention of the
aortic dilatation.
In the present study, we compared the AAA-preventable
effects of edaravone with two different doses (1 mg/kg/d
and 5 mg/kg/d). Edaravone treatment with the lower
dose was enough to suppress AAA formation, and the
treatment with the higher dose was more effective. Al-
thoughwe did not evaluate edaravone treatment with other
doses, we suggest that edaravone could prevent AAA for-
mation dose-dependently.
Edaravone has some clinical side effects, such as liver
and renal dysfunction and abnormal behavior with doses
30 mg/kg/d,35 but no side effects were noted with
edaravone at 1 or 5 mg/kg/d in this study. We believe that
edaravone has beneficial antioxidative actions as long as the
dose is optimal. Further study with other doses of edara-
vone will be necessary to evaluate its dose-dependent ef-
fects on AAA prevention.
A revolutionary finding in the present study was that
edaravone could prevent further aneurysm development.
Because human AAAs are always pre-existing when they are
found, it is very important to demonstrate in the experi-
mental setting whether a pharmacologic treatment can
induce AAA regression. Effective AAA pharmacotherapy
might be of significant benefit to many patients with small
AAAs or who are refused surgical procedures because of
Fig 8. Intra-aortic messenger RNA expression of tu
metalloproteinase (MMP)-2, and MMP-9 in the aneury
deviation (error bars) for six rats per group. Statistical anal
Games-Howell test. *P  .01, **P  .05 vs group C
administration as a control; Group LD, rats received lo
high-dose edaravone (5 mg/kg/d).poor general condition. oIn our rat AAA model, the aortic dilation ratio had
eached50% at day 7, and local production of proinflam-
atory cytokines andMMPs in AAA walls had upregulated
ignificantly.12 Because we regarded this AAA condition as
imulating the pre-existing form or a small AAA in humans,
daravone was given beginning 7 days after aneurysm prep-
ration. The present study showed that edaravone treat-
ent starting at 7 days after aneurysm preparation inhibited
AA further development. Previously, Yoshimura et al36
howed the first evidence of pharmacologic regression of
stablished AAAs by c-Jun N-terminal kinase inhibitor
SP600125), but this pharmaceutical agent has never been
sed clinically. Because edaravone has been already used as
free-radical scavenger in patients with acute cerebral
nfarction, we believe that edaravone has a high potential
or clinical pharmacotherapy for AAA regression. Further
tudies are necessary to elucidate the clinical efficacy of
daravone treatment for patients with pre-existing AAA.
This study presents some limitations. The first is that
he present rat AAAmodel induced by elastase and CaCl2 is
ot completely similar to the human AAA because it lacks
everal prominent features of the human lesion, such as
therosclerosis and intraluminal thrombosis. However, we
emonstrated that our AAA model is simple and easy to
erform, is highly reliable, and is reproducible to create a
accular aneurysm.12
The second limitation is the lack of protein analysis for
roinflammatory cytokines andMMPs and signal transduc-
ion mechanism analysis for the antioxidative effects of
daravone. The most likely mechanism for the protective
ffect of edaravone is a reduction in oxygen radicals, but
urther studies are needed, especially with regard to its
ffects on inflammatory cell infiltration and to exclude
necrosis factor (TNF)-, interleukin (IL)-1, matrix
all at day 7. All data are expressed as mean  standard
as done using one-way analysis of variance with post hoc
 0.01 vs group LD. Group C, Rats received saline
se edaravone (1 mg/kg/d); Group HD, rats receivedmor
sm w
ysis w
, †P
w-dother possible mechanisms of AAA regression.
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Volume 55, Number 6 Morimoto et al 1757The third limitation is that aortic wall thickness was not
measured under physiologic conditions by using perfusion-
fixed samples because of sample limitation. The harvested
sample was divided into three portions, with each portion
being analyzed for histologic examination, DHE stain, and
real-time PCR analysis, respectively. If the perfused fixation
had been done, we could not have evaluated the sample by
DHE stain and real-time PCR analysis.
CONCLUSIONS
The present study demonstrated that edaravone can
prevent not only aneurysm formation but also aneurysm
development with ROS inhibition in the rat AAA model.
The free-radical scavenger edaravone has a promising po-
tential for AAA pharmacotherapy that has not been estab-
lished clinically.
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Fig 9. Effect of delayed administration of edaravone. All data are
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group. A, Aortic dilatation ratio (%). B, Aortic wall thickness and
elastin content at day 28. Group C, Rats received saline adminis-
tration as a control; Group DA, rats received delayed administra-
tion of edaravone (5 mg/kg/d) starting at day 7. *P  .001 vs
group C. NS, Not significant.real-time PCR analysis.UTHOR CONTRIBUTIONS
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